Tokuyama (4043) Q4 2025 earnings summary

Executive summary

• Net sales and operating profit increased year-over-year, driven by strong semiconductor-related sales and manufacturing cost reductions.

• FY2025 net sales, operating profit, and ordinary profit are forecast to reach record highs, though below initial Medium-Term Plan targets.

• Annual dividend raised by ¥20 for two consecutive periods, with FY2024 year-end at ¥50/share and FY2025 interim and year-end at ¥60/share each; annual dividend for FY2025 planned at ¥120 per share.

• ROE improved to 9.2%, reflecting higher profitability, especially in the Electronic & Advanced Materials segment.

• Major healthcare acquisition (JSR's in vitro diagnostics and diagnostic materials businesses for ¥82 billion) to be completed October 1, 2025, accelerating portfolio transformation.

Financial highlights

• FY2024 net sales: ¥343.0B (+0.3% YoY); operating profit: ¥29.9B (+17% YoY); ordinary profit: ¥29.6B (+13% YoY); net income: ¥23.4B (+32% YoY).

• Basic EPS: ¥325.08 (FY2024), up from ¥246.72 (FY2023).

• Extraordinary income included gains from share transfers, reduction in cross-shareholdings, and sale of investment securities.

• Total assets as of Mar 31, 2025: ¥476.2B (+4.1% YoY); shareholders' equity: ¥261.5B; net assets: ¥273.9B.

• Cash and cash equivalents at year-end were ¥74.9B, up from ¥47.9B.

Outlook and guidance

• FY2025 forecasts: net sales ¥364.5B (+6% YoY), operating profit ¥41.5B (+38% YoY), ordinary profit ¥41.5B (+40% YoY), net income ¥29.0B (+24% YoY), EPS ¥403.09.

• Annual dividend for FY2025 planned at ¥120 per share.

• Focus on growth in electronics, health, and environment segments, with continued efficiency improvements in Chemicals and Cement.

• Semiconductor market expected to recover, especially in advanced applications; new dental materials facility completed.

• Uncertainty remains regarding US tariff policies and pending impact from JSR Corporation business acquisition.